Zeytin Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 46.86%
- Profit Growth 48.33%
- Ebitda 22.76%
- Net Worth 46.42%
- Total Assets 26.29%
About Zeytin Pharma
Zeytin Pharma Private Limited (ZPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 September 2018 (Six years and four months 25 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mosin Khatik and Sabir Sayyed serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999MH2018PTC314559
-
Company No.
314559
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Sep 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Zeytin Pharma Private Limited offer?
Zeytin Pharma Private Limited offers a wide range of products and services, including Popular Category, Bone & Joint Care, Vitamins & Supplements, Mineral Supplements, Women Care, Women Care Supplements.
Who are the key members and board of directors at Zeytin Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mosin Khatik
|
Director | 21-Sep-2018 | Current |
|
Sabir Sayyed
|
Director | 21-Sep-2018 | Current |
Financial Performance of Zeytin Pharma.
Zeytin Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 46.86% increase. The company also saw a substantial improvement in profitability, with a 48.33% increase in profit. The company's net worth Soared by an impressive increase of 46.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeytin Pharma?
Unlock access to Zeytin Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Incir Pharma Private LimitedSabir Sayyed is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zeytin Pharma?
Unlock and access historical data on people associated with Zeytin Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeytin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeytin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.